"Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, Chemotherapeutic Department with day pat
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bondarenko, Igor
NCT04129502 / 2019-001845-42: TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Checkmark [VIRTUAL] Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
Recruiting
3
318
Europe, Canada, US, RoW
TAK-788, AP32788, Pemetrexed, Alimta, Cisplatin, Carboplatin
Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
06/22
11/24
PRESERVE 1, NCT04607668 / 2019-003826-25: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Checkmark Approved Clinical Trial Application in China for metastatic CRC
Checkmark [VIRTUAL] PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Recruiting
3
296
Europe, US, RoW
Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo
G1 Therapeutics, Inc.
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
11/22
11/24
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Checkmark Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.
Checkmark [VIRTUAL] LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
Checkmark [VIRTUAL] LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
Recruiting
3
250
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
01/23
08/25
ARTEST, NCT04869943: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Recruiting
3
210
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
03/23
04/23
SELECT, NCT04549025 / 2019-004953-96: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Checkmark [VIRTUAL] Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
Checkmark Data from SELECT trial in combination with JTX-4014 for NSCLC at ASCO 2021
Recruiting
2
75
Europe, RoW
JTX-4014, Vopratelimab, JTX-2011
Jounce Therapeutics, Inc.
NSCLC
12/21
03/23
KEYNOTE-PN798, NCT03625323: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Checkmark From TACTI-002 trial in combination with Keytruda for 2L HNSCC at SITC 2021
Checkmark Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
Checkmark From TACTI-002 trial in combination with Keytruda for 2L HNSCC
Checkmark [VIRTUAL] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Checkmark From TACTI-002 trial in combination with Keytruda for NSCLC at ASCO 2021
More
Recruiting
2
183
Europe, US, RoW
Eftilagimod alpha, IMP321, Efti, Pembrolizumab, Keytruda, MK-3475
Immutep S.A.S., Merck Sharp & Dohme Corp.
NSCLC, HNSCC
05/22
05/23
SPARTA, NCT03175224 / 2019-001757-54: APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Checkmark [VIRTUAL] Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor
Checkmark [VIRTUAL] A whole transcriptome sequencing (WTS)-based cMet dysregulation biomarker assay with correlates to cMet DNA mutations and cMet protein expression.
Recruiting
1/2
201
Europe, Canada, US, RoW
APL-101 Oral Capsules, PLB-1001, CBI-3103, Bozitinib, CBT-101, Vebreltinib
Apollomics Inc.
Solid Tumor, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme
12/22
12/22
NCT03468426: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Checkmark [VIRTUAL] Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.
Checkmark [VIRTUAL] Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Checkmark [VIRTUAL] Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Checkmark Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Checkmark Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
More
Recruiting
1
305
Europe, Japan, US, RoW
BI 836880, ezabenlimab, BI 754091
Boehringer Ingelheim
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
02/23
06/23

Download Options